NovaBay Pharmaceuticals, Inc. (NBY) Financial Statements (2025 and earlier)

Company Profile

Business Address 2000 POWELL STREET, SUITE 1150
EMERYVILLE, CA 94608
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4303,1305,3627,50411,9526,937
Cash and cash equivalent4303,1305,3627,50411,9526,937
Receivables 3897591,9731,6681,1061,066
Inventory, net of allowances, customer advances and progress billings7652,8773,4373,220608492
Inventory7652,8773,4373,220608492
Prepaid expense4814917015216594
Asset, held-for-sale, not part of disposal group 48     
Other current assets11081113144102105
Other undisclosed current assets145158277482309687
Total current assets:1,9357,15411,33213,17014,2429,381
Noncurrent Assets
Operating lease, right-of-use asset9551,2961,8314114361,252
Property, plant and equipment538711919384110
Intangible assets, net (including goodwill)  (575)2,6289,728  
Goodwill   3484,528  
Intangible assets, net (excluding goodwill)  (575)2,2805,200  
Other noncurrent assets480497489476476477
Other undisclosed noncurrent assets  575    
Total noncurrent assets:1,4881,8805,06710,8089961,839
TOTAL ASSETS:3,4239,03416,39923,97815,23811,220
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,8802,6463,8043,1372,4172,109
Accounts payable6231,1301,0801,045302331
Accrued liabilities1,2571,5162,7242,0922,1151,778
Deferred revenue   4  434
Debt5651,137 105 2,339
Derivative instruments and hedges, liabilities      3
Other undisclosed current liabilities398495449200416802
Total current liabilities:2,8434,2784,2573,4422,8335,687
Noncurrent Liabilities
Long-term debt and lease obligation:    24687505
Liabilities, other than long-term debt7091,4421,588561  
Operating lease, liability7091,1081,58824687505
Business combination, contingent consideration, liability    561  
Derivative instruments and hedges, liabilities  334    
Other undisclosed noncurrent liabilities    9,558(87)4,055
Total noncurrent liabilities:7091,4421,58810,365874,560
Total liabilities:3,5525,7205,84513,8072,92010,247
Equity
Equity, attributable to parent, including:(129)3,31410,55410,17112,318973
Preferred stock    680  
Common stock49112652478418279
Additional paid in capital183,273176,101165,081150,900147,963125,718
Accumulated deficit(183,457)(174,849)(158,152)(141,887)(136,063)(125,024)
Other undisclosed equity, attributable to parent61,9502,973   
Total equity:(129)3,31410,55410,17112,318973
TOTAL LIABILITIES AND EQUITY:3,4239,03416,39923,97815,23811,220

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues9,78114,72614,4048,4219,9346,599
Cost of revenue
(Cost of Product and Service Sold)
(3,300)(6,831)(6,623)(2,776)(3,970)(1,738)
Gross profit:6,4817,8957,7815,6455,9644,861
Operating expenses(12,320)(15,491)(22,198)(14,507)(12,390) 
Operating income (loss):(5,839)(7,596)(14,417)(8,862)(6,426)4,861
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(550)(2,064)(276)(1,577)605 
Interest and debt expense(13)    (18)
Income (loss) from continuing operations before equity method investments, income taxes:(6,402)(9,660)(14,693)(10,439)(5,821)4,843
Other undisclosed income (loss) from continuing operations before income taxes  204,0854,615(5,213)(14,495)
Loss from continuing operations before income taxes:(6,402)(9,640)(10,608)(5,824)(11,034)(9,652)
Income tax expense     (5) 
Loss from continuing operations:(6,402)(9,640)(10,608)(5,824)(11,039)(9,652)
Loss before gain (loss) on sale of properties:(5,824)(11,039)(9,652)
Net loss:(6,402)(9,640)(10,608)(5,824)(11,039)(9,652)
Other undisclosed net income (loss) attributable to parent(821)    (6)
Net income (loss) attributable to parent:(7,223)(9,640)(10,608)(5,824)(11,039)(9,658)
Preferred stock dividends and other adjustments(1,385)(7,057)(5,657)(735) (829)
Net income (loss) available to common stockholders, diluted:(8,608)(16,697)(16,265)(6,559)(11,039)(10,487)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(6,402)(9,640)(10,608)(5,824)(11,039)(9,652)
Comprehensive loss, net of tax, attributable to parent:(6,402)(9,640)(10,608)(5,824)(11,039)(9,652)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: